Evidence map›Paper›PMID 38289534›Full record

ArticleJournal of neurology2024

Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.

Albulena Bajrami, Agnese Tamanti, Angela Peloso, Stefano Ziccardi, Maddalena Guandalini, Milena Calderone, Marco Castellaro, Francesca B Pizzini, Stefania Montemezzi, Damiano Marastoni and 1 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Albulena BajramiNeurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico "G.B. Rossi" Borgo Roma Piazzale L.A. Scuro, 10, 37134, Verona, Italy.ORCID http://orcid.org/0000-0002-6322-9545
Agnese TamantiNeurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico "G.B. Rossi" Borgo Roma Piazzale L.A. Scuro, 10, 37134, Verona, Italy.
Angela PelosoNeurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico "G.B. Rossi" Borgo Roma Piazzale L.A. Scuro, 10, 37134, Verona, Italy.
Stefano ZiccardiNeurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico "G.B. Rossi" Borgo Roma Piazzale L.A. Scuro, 10, 37134, Verona, Italy.ORCID http://orcid.org/0000-0003-0426-7223
Maddalena GuandaliniNeurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico "G.B. Rossi" Borgo Roma Piazzale L.A. Scuro, 10, 37134, Verona, Italy.ORCID http://orcid.org/0000-0003-2341-9253
Milena CalderoneRadiology Unit, Cmsr Veneto Medica S.R.L., Altavilla Vicentina, via Vicenza, 204, 36077, Vicenza, Italy.
Marco CastellaroDepartment of Information Engineering, University of Padova, Via Giovanni Gradenigo, 6b , 35131, Padua, Italy.ORCID http://orcid.org/0000-0002-1203-2670
Francesca B PizziniDepartment of Diagnostics and Public Health, University of Verona, Policlinico "G.B. Rossi" Borgo Roma Piazzale L.A. Scuro, 10, 37134, Verona, Italy.ORCID http://orcid.org/0000-0002-6285-0989
Stefania MontemezziDepartment of Diagnostics and Public Health, University of Verona, Policlinico "G.B. Rossi" Borgo Roma Piazzale L.A. Scuro, 10, 37134, Verona, Italy.
Damiano MarastoniNeurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico "G.B. Rossi" Borgo Roma Piazzale L.A. Scuro, 10, 37134, Verona, Italy.ORCID http://orcid.org/0000-0003-0358-9431
Massimiliano CalabreseNeurology B, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Policlinico "G.B. Rossi" Borgo Roma Piazzale L.A. Scuro, 10, 37134, Verona, Italy. massimiliano.calabrese@univr.it.ORCID http://orcid.org/0000-0002-3362-7403
University of Verona · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOcrelizumab (OCR) and Fingolimod (FGL) are two high-efficacy treatments in multiple sclerosis which, besides their strong anti-inflammatory activity, may limit neurodegeneration.

aimTo compare the effect of OCR and FGL on clinical and MRI endpoints.

methods95 relapsing-remitting patients (57 OCR, 38 FGL) clinically followed for 36 months underwent a 3-Tesla MRI at baseline and after 24 months. The annualized relapse rate, EDSS, new cortical/white matter lesions and regional cortical and deep grey matter volume loss were evaluated.

resultsOCR reduced the relapse rate from 0.48 to 0.04, FGL from 0.32 to 0.05 (both p < 0.001). Compared to FGL, OCR-group experienced fewer new white matter lesions (12% vs 32%, p = 0.005), no differences in new cortical lesions, lower deep grey matter volume loss (- 0.12% vs - 0.66%; p = 0.002, Cohen's d = 0.54), lower global cortical thickness change (- 0.45% vs - 0.70%; p = 0.036; d = 0.42) and reduced cortical thinning/volume loss in several regions of interests, including those of parietal gyrus (d-range = 0.65-0.71), frontal gyrus (d-range = 0.47-0.60), cingulate (d-range = 0.41-0.72), insula (d = 0.36), cerebellum (cortex d = 0.72, white matter d = 0.44), putamen (d = 0.35) and thalamus (d = 0.31). The effect on some regional thickness changes was confirmed in patients without focal lesions.

conclusionsWhen compared with FGL, patients receiving OCR showed greater suppression of focal MRI lesions accumulation and lower cortical and deep grey matter volume loss.

Indexed as

Antibodies, Monoclonal, HumanizedFingolimod HydrochlorideGray MatterMagnetic Resonance ImagingMultiple Sclerosis, Relapsing-RemittingAdultCerebral CortexFemaleFollow-Up StudiesHumansImmunologic FactorsMaleMiddle AgedSphingosine 1 Phosphate Receptor ModulatorsAntibodies, Monoclonal, HumanizedFingolimod HydrochlorideImmunologic FactorsocrelizumabSphingosine 1 Phosphate Receptor ModulatorsBrain atrophyCortical lesionsMultiple sclerosisNeurodegenerationOcrelizumab

Identifiers

PMID38289534
PMCPMC11055717
OpenAlexW4391355463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.